Linear Clinical Research

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 390 citations

Lymphoid Neoplasia, Bispecific Antibody, Medicine +7

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond, Lara Hatchuel, Min Dong et al. · The Lancet · 2021 · 279 citations · Full text

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown et al. · New England Journal of Medicine · 2023 · 190 citations · Full text

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline et al. · Blood · 2019 · 179 citations